Expertise in
30
conditions

Dr. Luciano J. Costa

Hematology Oncology | Hematology | Oncology
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
30
conditions
University Of Alabama Health Services Foundation, PC
619 19th St S, 
Birmingham, AL 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Luciano Costa is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Costa is highly rated in 30 conditions, according to our data. His top areas of expertise are Multiple Myeloma, Smoldering Multiple Myeloma, Plasmacytoma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Costa is currently accepting new patients.

His clinical research consists of co-authoring 212 peer reviewed articles and participating in 7 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Hematology
Oncology
Licenses
Internal Medicine in AL
Hospital Affiliations
University Of Alabama Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO

Locations

UNIVERSITY OF ALABAMA HEALTH SERVICES FOUNDATION, PC
619 19th St S, Birmingham, AL 35249

Additional Areas of Focus

Dr. Costa has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia - MILESTONE Trial
Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia - MILESTONE Trial
Enrollment Status: Recruiting
Publish Date: November 27, 2024
Intervention Type: Drug
Study Phase: Phase 2
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Phase II Study for Standardization of CD3+ T Cell Dose for Patients Receiving Allogeneic Peripheral Blood Stem Cell Transplants from Matched Related Donors
Enrollment Status: Active_not_recruiting
Publish Date: December 20, 2024
Intervention Type: Device
Study Phase: Not Applicable
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Protocol H125001: An Open-Label Phase 1/2 Study of JCARH125, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: May 24, 2024
Intervention Type: Biological
Study Drugs: JCARH125, JCARH125 + Anakinra
Study Phase: Phase 1/Phase 2
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Single Arm Phase II Study of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia (ALL) in Older Patients Using Fludarabine and Total Body Irradiation (FluTBI) Regimen
Enrollment Status: Completed
Publish Date: January 12, 2024
Intervention Type: Drug, Procedure
Study Drug: Fludarabine
Study Phase: Phase 2
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
A Phase 2b, Open-Label, Single-Arm Study of Selinexor (KPT-330) Plus Low-Dose Dexamethasone (Sd) in Patients With Multiple Myeloma Previously Treated With Lenalidomide, Pomalidomide, Bortezomib, Carfilzomib, and an Anti-CD38 Monoclonal Antibody (mAb) Daratumumab, and Refractory to Prior Treatment With Glucocorticoids, an Immunomodulatory Agent, a Proteasome Inhibitor, and an the Anti-CD38 mAb Daratumumab
Enrollment Status: Completed
Publish Date: January 26, 2023
Intervention Type: Drug
Study Phase: Phase 2
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Phase II Clinical Trial of the Use of Post-Transplant Cyclophosphamide for Graft Versus Host Disease (GvHD) Prophylaxis Following Matched Unrelated Donor (MUD) and Mismatched Unrelated Donor (MMUD)Hematopoietic Stem Cell Transplant (HSCT)
Enrollment Status: Completed
Publish Date: September 30, 2022
Intervention Type: Drug
Study Drug: Cyclophosphamide
Study Phase: Phase 2
View 6 Less Clinical Trials

212 Total Publications

Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies.
Correction to: Evolution of frontline treatment for multiple myeloma: clinical investigation of quadruplets containing carflzomib and antiCD38 monoclonal antibodies.
Journal: Annals of hematology
Published: March 31, 2025
Similar Doctors
Expertise in
18
conditions
Dr. Gaurav N. Goyal
Hematology Oncology | Hematology | Oncology
Expertise in
18
conditions
Dr. Gaurav N. Goyal
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (0.1 mi)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gaurav Goyal is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Goyal is highly rated in 18 conditions, according to our data. His top areas of expertise are Histiocytosis, Reticulohistiocytoma, Non-Langerhans-Cell Histiocytosis, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Goyal is currently accepting new patients.

Expertise in
36
conditions
Dr. Amitkumar N. Mehta
Hematology Oncology | Hematology | Oncology
Expertise in
36
conditions
Dr. Amitkumar N. Mehta
Hematology Oncology | Hematology | Oncology

University Of Alabama Health Services Foundation, PC

619 19th St S, 
Birmingham, AL 
 (0.1 mi)
205-934-4011
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Amitkumar Mehta is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Mehta is highly rated in 36 conditions, according to our data. His top areas of expertise are Non-Hodgkin Lymphoma, B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Bone Marrow Aspiration, and Tissue Biopsy. Dr. Mehta is currently accepting new patients.

Andres F. Forero-Torres
Expertise in
24
conditions
Dr. Andres F. Forero-Torres
Hematology Oncology | Hematology | Oncology
Expertise in
24
conditions
Dr. Andres F. Forero-Torres
Hematology Oncology | Hematology | Oncology
619 19th St S, 
Birmingham, AL 
 (0.1 mi)
205-934-6600
Languages Spoken:
English
See accepted insurances

Andres Forero-Torres is a Hematologist Oncology specialist and a Hematologist in Birmingham, Alabama. Dr. Forero-Torres is highly rated in 24 conditions, according to our data. His top areas of expertise are Hodgkin Lymphoma, HER-2 Positive Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Costa's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 21 Advanced Conditions
View All 25 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile